Ganetespib "ripe for partnership": Roth

|By:, SA News Editor

Roth Capital is out with some positive commentary on Synta Pharmaceuticals (SNTA +10.5%) following the announcement of new clinical trials for ganetespib

"We continue to look towards interim analysis from the GALAXY-2 trial in NSCLC in H2 and top-line data in H1 2015," analyst Joseph Pantginis says, adding that "as the ganetespib profile continues to broaden, [he] continues to believe that the drug is ripe for a partnership in the relative near term."

Price target is $27, representing upside of 295% from Thursday's close.